Emami Ltd Q3 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/sha074lx28i1y4bgyxvo1jm7.pdf

Key Takeaways


Demand & Volume Performance

Mohan Goenka: "The month of January, we haven't seen the kind of growth what we had seen in the last few weeks of December. So we will have to wait and watch for the complete recovery I think. It may take a while. I'm not too sure."

Margins & Cost Structure

Mohan Goenka: "In line with our guidance shared in the last con call, we believe this would be the last quarter for margin contraction."

International Business

Vivek Dhir: "Every brand in quarter 3 has delivered a growth except one brand, where we had some unplanned maintenance in the factory and we couldn't supply those goods when this happened. And those standing orders will be delivered in this quarter."

Strategic Initiatives & Portfolio Moves


FY24 Growth Outlook

Mohan Goenka: "We are very hopeful that next year we are definitely going to see at least 10% to 12% growth, is what we should expect from most of the product range. Of course, the market sentiments have to improve. But even though, not considering the market, I think we should grow at double-digit numbers."

Guidance & Commitments

CommitmentSpecificsTimeline
Gross margin expansionYoY gross margins to improve from Q4 as raw material pressure easesQ4 FY23 onwards
Full-year EBITDA marginCore business EBITDA margin at pre-COVID level of ~27%FY23
International back ordersPending orders from factory outage to be delivered; most completedBy March 2023
Healthcare growth accelerationGrowth to pick up once high base effect wears out, driven by NPDQ1 FY24 onwards
FY24 revenue growthAt least 10% to 12% growth from most of the product rangeFY24
MAT credit availabilityMAT credit to continue, keeping tax rate at roughly 10% to 12%FY24

Key Metrics

MetricQ3 FY23
Net sales₹975 cr, grew 2% YoY; 3-year CAGR of 7%
Revenues₹983 cr, grew 1% YoY
Domestic business growth1% YoY; 3-year CAGR of 6%
Domestic volumes-3.9% YoY
International business growth7% YoY; 3-year CAGR of 13%
Gross margin65.9%, contracted 150 bps YoY
EBITDA₹294 cr, declined 14% YoY
Profit after tax₹237 cr, grew 8% YoY
Core business EBITDA margin guidance (FY23)~27%, excluding The Man Company
Tax rate guidance10% to 12%, considering MAT credit
Employee cost₹93 cr in Q3; expected regular run-rate ~₹90 cr per quarter
E-commerce contribution to domestic revenues7.9%, up 260 bps YoY
Modern trade contribution to domestic revenues10.5%, up 200 bps YoY
Modern trade + e-commerce combined contribution18.4% of domestic revenues, vs 13.8% in Q3 last year
Modern trade growth20% YoY
E-commerce growth45% YoY
Healthcare range growth2% YoY; 3-year CAGR of 8%
7 Oils in One growth5% YoY; 3-year CAGR of 13%
BoroPlus range growth-3% YoY; 3-year CAGR of 5%
Pain Management range growth-2% YoY; 3-year CAGR of 6%
Kesh King growth-1% YoY; 3-year CAGR of 4%
Navratna growth-6% YoY
Male Grooming range growth-1% YoY; 3-year CAGR marginal
The Man Company contribution to net sales2.8% of overall net sales
NPDs contribution to domestic net sales~4%
New/digital-first launches share in modern trade & e-commerce14% of sales in those channels
OTC to Ethical mix ratio~2.5 : 1
Project Khoj business generated (9M FY23)~₹67 cr till date; expected ~₹83–85 cr by year-end
Total rural cost (sub-stockist channel)~6% of sales; network cost up ~7.8%
International business growth (9M FY23)Close to 20%
Second interim dividend₹4 per share (400%)